Key Takeaways
- Fourth-quarter revenue reached $9.81 billion, surpassing analyst projections of $9.63 billion.
- Adjusted earnings per share of $1.55 exceeded the Street’s $1.54 consensus forecast.
- Cardiovascular division revenue climbed 13.8% to $3.8 billion, with Cardiac Ablation Solutions skyrocketing 78% worldwide.
- Fiscal 2027 adjusted EPS outlook of $5.90–$6.00 fell short of the $6.06 analyst consensus; tariff challenges expected to reach approximately $300 million.
- Quarterly dividend increased to $0.72 per share, extending the company’s dividend growth streak to 49 consecutive years.
Medtronic delivered its most impressive annual revenue expansion in ten years, fueled by explosive growth in cardiovascular technologies. The medical device giant reported fourth-quarter revenue of $9.81 billion, topping Wall Street’s $9.63 billion projection, while adjusted earnings of $1.55 per share narrowly beat the $1.54 estimate. Full-year organic revenue growth reached 5.8%, representing the company’s strongest yearly performance in a decade.
While the topline results impressed, certain areas revealed weakness — particularly the fiscal 2027 earnings guidance of $5.90 to $6.00 per share, which missed analyst expectations of $6.06.
Trade-related expenses represent a tangible challenge. Management anticipates approximately $300 million in tariff-related costs during fiscal 2027, a significant increase from the roughly $185 million burden faced in fiscal 2026. The company has been transparent about these financial headwinds.
Cardiac Technologies Lead Performance
The cardiovascular division emerged as the clear powerhouse this quarter. Sales surged 13.8% to $3.8 billion — accounting for nearly 40% of consolidated revenue. Cardiac Ablation Solutions exploded with 78% global growth, including exceptional 124% expansion in the United States, capturing an additional 8 percentage points of market share.
Pulsed field ablation technology and transcatheter aortic valve replacement procedures represent the fastest-growing treatment modalities currently, with Medtronic establishing substantial competitive positioning in both categories.
The Micra leadless pacemaker system delivered mid-teens percentage growth, while the OmniaSecure defibrillation lead experienced a successful domestic market introduction.
Neuroscience division revenue increased 5% to $2.75 billion, slightly below the $2.76 billion Street estimate. The Medical Surgical segment generated $2.39 billion, representing 8% reported growth and 5.1% organic expansion, with the Acute Care & Monitoring category achieving low double-digit percentage gains.
Diabetes revenue jumped 15% on a reported basis to $837 million, and this division remains fully integrated within Medtronic throughout the entire fiscal 2027 guidance period.
Strategic Acquisitions and Product Pipeline
Medtronic has pursued an aggressive tuck-in acquisition strategy following its diabetes business separation. Throughout the quarter and fiscal year, the company completed the CathWorks transaction, revealed agreements to acquire Scientia Vascular and SPR Therapeutics (valued at approximately $650 million combined), and submitted regulatory applications to the FDA for its Hugo robotic-assisted surgical system covering general surgery and gynecologic procedures.
The Hugo regulatory submission marks a critical milestone in the company’s surgical robotics strategy — a competitive arena where Medtronic has been methodically building capabilities.
The company also elevated its quarterly dividend payment to $0.72 per share, extending its remarkable dividend growth track record to 49 consecutive annual increases.
Looking ahead to fiscal 2027, Medtronic projects organic revenue growth between 6.75% and 7.25%. Full fiscal year 2026 revenue totaled $36.4 billion, representing 8.4% reported growth and 5.8% organic expansion.
